PDUFA and BsUFA Reauthorization: Key Changes Affecting Industry and Patients

Quantity

Back to Results

Recorded September 12, 2017 | On-Demand Webinar

The agreement effectuated by the fifth reauthorization of the Prescription Drug User Fee Act (PDUFA VI) and the first reauthorization of the Biosimilars User Fee Act (BsUFA) substantially alter the fee structures of these programs and provide resources for FDA to carry out significant activities detailed in the letters of agreement between FDA and stakeholders. In this webinar, key stakeholders will describe the PDUFA and BsUFA agreements, highlight major changes, and identify implementation issues to watch. Following panelist presentations, there will be discussion of key issues among the panelists and an opportunity to ask questions.

Kay Holcombe, Senior Vice President, Science Policy, Biotechnology Innovation Organization (BIO)
Lucy Vereshchagina, Vice President, Science & Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America (PhRMA)
Jeff Allen, President and CEO, Friends of Cancer Research (Friends)
Jeffrey K. Francer, Senior Vice President & General Counsel, Association for Accessible Medicines (AAM)

Moderated by Elizabeth Jungman, Director, Public Health Programs, The Pew Charitable Trusts

IE and Edge users: Microsoft Internet Explorer (IE) and Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you in your purchase.

Assign Members :

Members Assigned | Assign all contacts Unassign all contacts

Add New Contact

Assign	Full Name	Account Name	Email	Role

Total Records - Showing Page

Add New Contact

Discounts and special pricing for additional items will be applied once you add the item to your cart.